help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. 3, 306-315, March 2006; doi:10.1634/theoncologist.11-3-306
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 The Role of Statins in Cancer Therapy
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hindler, K.
Right arrow Articles by Collard, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hindler, K.
Right arrow Articles by Collard, C. D.

The Role of Statins in Cancer Therapy

Katja Hindlera, Charles S. Cleelandb, Edgardo Riverac, Charles D. Collarda

a Division of Cardiovascular Anesthesiology, Texas Heart® Institute, St. Luke’s Episcopal Hospital, Houston, Texas, USA; b Department of Symptom Research and c Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

Key Words. HMG-CoA reductase inhibitor • Tumor • Chemotherapy • Inflammation • Prevention

Charles D. Collard, M.D., Division of Cardiovascular Anesthesiology, The Texas Heart® Institute at St. Luke’s Episcopal Hospital, 6720 Bertner Avenue, Room 0520, MC1-226, Houston, Texas 77030, USA. Telephone: 832-355-2666; Fax: 832-355-6500; e-mail: ccollard{at}heart.thi.tmc.edu

Administration of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, to ambulatory patients is associated with a lower incidence of long-term adverse cardiovascular events, including death, myocardial infarction, stroke, atrial fibrillation, and renal dysfunction. However, increasing clinical evidence suggests that statins, independent of their effects on serum cholesterol levels, may also play a potential role in the prevention and treatment of cancer. Specifically, statins have been shown to exert several beneficial antineo-plastic properties, including decreased tumor growth, angiogenesis, and metastasis. The feasibility and efficacy of statins for the prevention and treatment of cancer is reviewed.




This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. S. Kumar, C. C. Benz, V. Shim, C. A. Minami, D. H. Moore, and L. J. Esserman
Estrogen Receptor-Negative Breast Cancer Is Less Likely to Arise among Lipophilic Statin Users
Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1028 - 1033.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Sonnemann, B. Bumbul, and J. F. Beck
Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro
Mol. Cancer Ther., November 1, 2007; 6(11): 2976 - 2984.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2006 by AlphaMed Press.